Top Markets
Coin of the day
Cyxone AB (publ) Cyxone AB (publ)

Cyxone AB (publ)

CYXO
株式のランク #40403
Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing... Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in Malmö, Sweden.
株価
$0.00162013
最終同期: 2025-01-03
時価総額
$156.25K
変化(1日)
0.36%
変化(1年)
0.00%
SE
取引 Cyxone AB (publ) (CYXO)

カテゴリー

Cyxone AB (publ)(CYXO)の利益
Jun 2024 時点の利益 TTM: $-2.04M
Cyxone AB (publ) の最新の財務報告によると、同社の現在の利益は $-2.04M です。2022 年には $-4.07M の利益を上げ、これは 2021 年の利益 $-4.98M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Cyxone AB (publ) の利益の推移(2015 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-2.04M -10.32%
2023 $-2.28M -44.05%
2022 $-4.07M -18.14%
2021 $-4.98M -16.09%
2020 $-5.93M 57.40%
2019 $-3.77M 118.05%
2018 $-1.73M 60.09%
2017 $-1.08M 135.58%
2016 $-458.07K -2,484.88%
2015 $19.21K 0.00%
同業他社の利益
企業 利益 利益の差
$5.27B -258,252.37%
US
$1.95B -95,564.36%
NL
- -
CH
- -
KR
$3.01B -147,199.10%
BE